Revenue of $191.57M (+335.9% Y/Y) beats by $162.54M.
Thursday, August 8, 2019
FibroGen EPS of $1.26
FibroGen (NASDAQ:FGEN): Q2 EPS of $1.26 may not be comparable to consensus of -$0.55.
BioLife Solutions EPS beats by $0.02, beats on revenue
BioLife Solutions (NASDAQ:BLFS): Q2 Non-GAAP EPS of $0.04 beats by $0.02; GAAP EPS of $0.03 beats by $0.01.
Revenue of $6.7M (+29.3% Y/Y) beats by $0.05M.
Cytokinetics EPS misses by $0.06, beats on revenue
Cytokinetics (NASDAQ:CYTK): Q2 GAAP EPS of -$0.56 misses by $0.06.
Revenue of $7.1M (+14.5% Y/Y) beats by $0.11M.
ViewRay EPS misses by $0.08, beats on revenue
ViewRay (NASDAQ:VRAY): Q2 GAAP EPS of -$0.32 misses by $0.08.
Revenue of $30.17M (+83.5% Y/Y) beats by $4.25M.
Allscripts down 1% after hours on flat Q2 growth
Allscripts Healthcare Solutions (NASDAQ:MDRX) Q2 results ($M): Revenue: 444.5 (+1%); Software delivery, support & maintenance: 285.0 (flat); Client services: 159.5 (+2%).
Bookings: 276 (+31%).
Net income: (149.9) (-332%); non-GAAP net income: 28.7 (-11%); EPS: (0.90) (-350%); non-GAAP EBITDA: 75.3 (flat).
Cash flow ops: (7.7) (-194%).
2019 guidance: Bookings: $1,050M – 1,100M from $900M – 1,000M; non-GAAP EPS: $0.65 – 0.70 (unch).
Nektar Therapeutics EPS beats by $0.17, misses on revenue
Nektar Therapeutics (NASDAQ:NKTR): Q2 GAAP EPS of -$0.63 beats by $0.17.
Revenue of $23.3M (-97.9% Y/Y) misses by $3.35M.
Subscribe to:
Posts (Atom)